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Abstract
Context: To date, there is no Level 1 evidence comparing the efficacy of radical
prostatectomy and radiotherapy for patients with clinically-localized prostate cancer.
Objective: To conduct ameta-analysis assessing the overall and prostate cancer-speciﬁc
mortality among patients treated with radical prostatectomy or radiotherapy for
clinically-localized prostate cancer.
Evidence acquisition: We searchedMedline, EMBASE, and the Cochrane Library through
June 2015 without year or language restriction, supplemented with hand search, using
Preferred Reporting Items for Systematic Reviews andMeta-Analysis andMeta-analysis
of Observational Studies in Epidemiology guidelines. We used multivariable adjusted
hazard ratios (aHRs) to assess each endpoint. Risk of bias was assessed using the
Newcastle-Ottawa scale.
Evidence synthesis: Nineteen studies of low to moderate risk of bias were selected and
up to 118 830 patients were pooled. Inclusion criteria and follow-up length varied
between studies. Most studies assessed patients treated with external beam radiother-
apy, although some included those treated with brachytherapy separately or with the
external beam radiation therapy group. The risk of overall (10 studies, aHR 1.63, 95%
conﬁdence interval 1.54–1.73, p < 0.00001; I2 = 0%) and prostate cancer-speciﬁc
(15 studies, aHR 2.08, 95% conﬁdence interval 1.76–2.47, p < 0.00001; I2 = 48%)
mortality were higher for patients treated with radiotherapy compared with those
treated with surgery. Subgroup analyses by risk group, radiation regimen, time period,
and follow-up length did not alter the direction of results.
Conclusions: Radiotherapy for prostate cancer is associated with an increased risk of
overall and prostate cancer-speciﬁc mortality compared with surgery based on obser-
vational data with low to moderate risk of bias. These data, combined with the
forthcoming randomized data, may aid clinical decision making.
Patient summary: We reviewed available studies assessing mortality after prostate
cancer treatment with surgery or radiotherapy. While the studies used have a potential
for bias due to their observational design, we demonstrated consistently higher mor-
tality for patients treated with radiotherapy rather than surgery.
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Nonconservative treatment options for patients diagnosed
with clinically-localized prostate cancer include radical
prostatectomy and radiotherapy [1]. Currently, there are no
published randomized controlled trials comparing their
efficacy. For patients desiring nonconservative treatment,
established clinical guidelines recommend either treatment
option and patients must ultimately decide for themselves
which treatment to undertake [2,3].
Few reviews and meta-analyses have been published on
this subject. Recent reviews have focused on patients with
high-risk prostate cancer [4,5]. These have reported a benefit
of radical prostatectomy over radiotherapy for both overall
andprostate cancer specificmortality [4,5]. The limitedscope
of previous reviews and recent publication of a number of
studies assessing prostate cancer-specific and overall surviv-
al for patients treated with contemporary forms of radio-
therapy [6–8] requires a new, comprehensivemeta-analysis.
Our objective was to systematically review and conduct
a systematic review and meta-analysis to compare efficacy
data on overall and prostate cancer-specific survival among
patients treatedwith radiotherapy or radical prostatectomy
for clinically-localized prostate cancer.
2. Evidence acquisition
2.1. Research question
Do patients treated with radical prostatectomy for clinical-
ly-localized prostate cancer have improved overall or
prostate cancer-specific mortality compared with those
treated with radiotherapy?
2.2. Types of studies
We included randomized controlled trials, cohort, and case-
control studies. Case series lacking comparator groups were
excluded. Other publications including editorials, commen-
taries, and review articles were excluded. Publications not
subject to peer-review (ie, reports of data fromvital statistics
and dissertations or theses)were also excluded.Where there
was more than one publication resulting from the same
patient cohort, to prevent the duplication of patients from
one cohort, for each of our analyses we selected one study
based on a hierarchical assessment of comparability of study
groups, time period of study (preference for more recent),
and number of patients (Supplementary data).
2.3. Types of participants and exposure
We reviewed studies reporting on men of any age with
nonmetastatic prostate cancer treated with any commonly-
utilized form of radiotherapy including conformal external
beam (EBRT), intensity-modulated (IMRT), brachytherapy,
or a combination of radiotherapy modalities with curative
treatment intent. We excluded studies assessing adjuvant
or salvage therapies as the specific objective. We included
studies irrespective of dose and duration of radiotherapy. Inorder to be included, studies had to have a comparison
group comprising patients treated with radical prostatec-
tomy. Studies assessing nonstandard treatments (such as
cryotherapy) were excluded.
2.4. Outcome measures
The primary outcome was overall mortality and the
secondary outcome was prostate cancer-specific mortality.
Studies reporting surrogate endpoints such as biochemical
recurrence only were excluded. Since age, comorbidity, and
histologic factors such as grade and stage significantly
impact overall and prostate cancer-specific mortality [8,9],
we considered studies only reporting multivariable adjust-
ed hazard ratios (aHR). We excluded crude or unadjusted
outcome measures since these would provide biased
estimates given the known differences in age and comor-
bidity between patients treated with radiotherapy and
surgery.
2.5. Methods of review
We used Preferred Reporting Items for Systematic Reviews
and Meta-Analyses and Meta-analysis of Observational
studies in Epidemiology guidelines for reporting of this
systematic review and meta-analysis [10,11].
2.6. Search strategy
Medline, EMBASE, and EBM Reviews Cochrane Central
Register of Controlled Trials databases were searched using
the OvidSP search platform for studies indexed from
database inception to June 1, 2015 with the assistance of a
professional librarian. We used both subject headings and
text-word terms for ‘‘radical prostatectomy’’, ‘‘prostate
cancer surgery’’, ‘‘radiotherapy’’, ‘‘outcome’’, ‘‘survival/mor-
tality’’, and related and exploded terms including medical
subject headings terms in combination with keyword
searching. A full search strategy is presented in the
Supplementarydata.No limitationswereplacedwith respect
to publication language or publication year. Following the
literature search, all duplicates were excluded. References
from review articles, commentaries, editorials, included
studies, and conference publications of relevant medical
societies were reviewed and cross-referenced to ensure
completeness. Conference abstracts were excluded.
2.7. Review methods
Two authors performed the study selection independently
(C.J.D.W. and R.S.). Disagreements were resolved by
consensus with the senior author (R.K.N.). Titles and
abstracts were used to screen for initial study inclusion.
Full-text reviewwas used where abstracts were insufficient
to determine if the studymet inclusion or exclusion criteria.
The final list of selected studies was agreed upon by
urologists (C.J.D.W. and R.K.N.), radiation oncologists (R.C.
and C.D.), and an epidemiologist (R.S.). One author (C.J.D.W.)
performed all data abstraction including evaluation of study
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independent verification performed by other authors.
2.8. Risk of bias assessment
We used the Newcastle-Ottawa Scale for risk of bias
assessment. This scale assesses risk of bias in three domains
[12]: (1) selection of the study groups; (2) comparability of
groups; and (3) ascertainment of exposure and outcome
[13]. Studies with scores  7 were considered as having a
low risk of bias, scores of 4–6 as having a moderate risk of
bias, and scores < 4 as having a high risk of bias. We
assessed that follow-up was adequate if the median or
mean follow-up was in excess of 5 yr.
2.9. Measures of treatment effect
We assessed the aHR for mortality for patients treated with
radiotherapy and surgery.
2.10. Assessment of heterogeneity
We identified heterogeneity using the Q test, estimated it
using the DerSimonian-Laird method, and quantified it
using I2 values [14]. Furthermore, we employed random-
effects models for each of our analyses given the identified
clinical heterogeneity.
2.11. Assessment of reporting bias
We assessed publication bias for outcomes with more than
10 included studies using funnel plots.[(Fig._1)TD$FIG]
Fig. 1 – Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow2.12. Data synthesis
Meta-analysis was performed using Review Manager 5.3
(Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2014) software.We used the inverse variance
technique for meta-analysis of hazard ratios. Due to the
clinical heterogeneity inherent in our data, random-effects
models were used for all meta-analyses.
2.13. Subgroup analysis
We performed a number of a priori subgroup analyses. We
planned subgroup analyses restricted to EBRT, IMRT,
brachytherapy, and brachytherapy with EBRT boost. How-
ever, datawere only available for subgroup analyses of EBRT,
IMRT, and brachytherapy. We also performed subgroup
analysis assessingthe impactof: (1)prostate cancer risk stage
(low, intermediate, and high); (2) duration of follow-up (<5
yr, 5–8 yr, >8 yr); (3) study era (‘‘old’’ if the accrual started
prior to 1990or endedprior to 2005 and ‘‘newer’’ otherwise);
and (4) study location (USA and rest of the world).
We did not encounter any issues with repeated
measures, unit of analyses, or missing data.3. Evidence synthesis
Our literature search identified 1624 unique references
(Fig. 1). After full text review of 73 manuscripts, 19 were
selected for inclusion. The reasons for exclusion are
provided in Figure 1 and the Supplementary data. In
particular, there were multiple publications arising fromdiagram outlining search strategy and final included and excluded studies.
Table 1 – Characteristics of included studies
Author (yr) Data source (study interval) Follow–up
(median)
Inclusion criteria Radiation
modality
Radiation dose Study
size
Adjuvant
therapies
Age Outcome
RP XRT
Abdollah (2012) SEER (1992–2005) 52 mo Clinically localized,
age 65–79
Unspeciﬁed NA 68 665 ADT:
RP: 0%
XRT: 9%
65–69: 53%
70–74: 39%
75–79: 9%
65–69: 24%
70–74: 41%
75–79: 35%
PCM
Albersten (2007) Connecticut Tumor Registry
(1992–2005)
Mean 13.3 yr Clinically localized,
age < 75
EBRT NA 1618 Excluded median 65 median 71 PCM
Arvold (2011) 21st Century Oncology, Chicago
Prostate Centre, Duke University
(1988–2008)
6.1 yr (RP) and
3.6 yr (XRT)
Low risk or
intermediate riska
Brachy min 115 Gy 8839 Included but
proportion not
speciﬁed
median low
risk: 61.4; int
risk: 62.9
median low
risk: 68.8; int
risk: 71.2
PCM
Boorjian (2011) Mayo Clinic, Fox Chase (1988–2004) 10.2 yr (RP) and
6.0–7.3 yr (XRT)
High riska EBRT
(conformal, 3DCRT,
IMRT)
median 72 Gy
(range, 50–79)
1847 ADT:
RP: not speciﬁed
XRT: 56%
median 66.0 median with
ADT: 68.8; no
ADT: 69.3
OM, PCM
Cooperberg
(2010)
CaPSURE (1987–2007) 3.9 yr (RP) and
4.5 yr (XRT)
Clinically localized EBRT NA 6209b ADT
RP: 6.7%
XRT: 49.7%
Postop XRT: 3%
median 62 median 72 OM, PCM
DeGroot (2013) Ontario Cancer Registry (1990–1998) NR ‘‘Candidate for
therapy’’: low and
intermediate riska
EBRT median 64 Gy
(range, 40–70)
1090 ADT
RP: 29%
XRT: 22%
mean 63 mean 69 PCM
Hoffman (2013) PCOS (1994–2010) 15 yr Clinically localized,
age 55–74
EBRT NA 1655 ADT:
RP: 0%
XRT: 11%
55–64: 52%
65–74: 48%
55–64: 23%
65–74: 77%
OM, PCM
Jeldres (2008) Quebec Health Plan (1989–2000) 7.4 yr Age > 70 EBRT NA 6183 Included but
proportion not
speciﬁed
median 71 median 74 OM
Kibel (2012) Barnes–Jewish Hospital (BJ),
Cleveland Clinic (CC) (1995–2005)
67 mo Clinically localized EBRT (3DCRT,
IMRT), brachy
median 74 Gy (BJ)
and 78 Gy (CC)
10 429 ADT:
RP: not speciﬁed
XRT: 34%
median
BJ: 61;
CC: 60
median
BJ–EBRT: 70;
BJ–brachy: 69;
CC–EBRT: 69;
CC–brachy: 68
OM, PCM
Ladjevardi (2010) Swedish National Prostate Cancer
Registry (1996–2006)
4.4 yr T1–3, N0–X, M0–X,
PSA < 20, age < 75
EBRT, brachy NA 19 258c Not speciﬁed <55: 10%
55–59: 23%
60–64: 33%
65–69: 27%
70–75: 8%
<55: 4%
55–59: 13%
60–64: 25%
65–69: 33%
70–75: 25%
OM
Lee (2014) Severance Hospital, Seoul Korea
(1990–2009)
76 mo Clinically localized
high riska
EBRT 74–79 Gy 376 ADT
RP: 0%
XRT: 100%
Postop XRT: 10%
mean 67.5 mean 68.6 PCM
Merglen (2007) Geneva Cancer Registry (1989–1998) 6.8 yr Clinically localized EBRT NA 363 ADT
RP: not speciﬁed
XRT: 26%
<60: 23%
60–69: 52%
70–79: 18%
80: 7%
<60: 9%
60–69: 52%
70–79: 38%
80: 1%
OM, PCM
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Merino (2013) Pontiﬁcia Universidad Catolica de
Chile (1999–2010)
92 mo (RP) and
76 mo (XRT)
Clinically localized IMRT 76 Gy 1200 ADT:
RP: 0%
XRT: 42%
Postop XRT: 5%
mean 63 mean 70 PCM
Rice (2013) CPDR (1989–2009) 6.4 yr Low riska, age > 70 EBRT NA 446d Not speciﬁed mean 72.2 mean 74.1 OM
Sooriakumaran
(2014)
PcBaSe Sweden (1996–2010) 5.4 yr All Unspeciﬁed NA 32 846e Not speciﬁed median 62 median 66 PCM
Sun (2013) SEER (1998–2005) NR Clinically localized,
age 65–80
EBRT, brachy NA 49 145f Not speciﬁed median 69 median 73 OM, PCM
Tewari (2007) Henry Ford Health System (1980–
1997)
68 mo (RP) and
54 mo (XRT)
Clinically localized,
high riska, age < 75
Unspeciﬁed NA 256g ADT.
RP: 18.5%
XRT: 19%
mean 62.9 mean 68.0 OM, PCM
Westover (2012) 21st Century Oncology, Chicago
Prostate Centre, Duke University
(1988–2008)
4.6 yr Clinically localized,
Gleason score 8–
10, age < 75
Combination
EBRT+brachy
45 Gy EBRT + min
90–108 Gy brachy
657 ADT
RP: 6%
XRT: 100%
Postop XRT: 6%
median 65 median 70 PCM
Zelefsky (2010) Baylor College, Memorial Sloan
Kettering (1993–2002)
5.1 yr (RP) and
5.0 yr (XRT)
T1c–T3b IMRT 81 Gy (79%) or
86.4 Gy (21%)
2380 ADT
RP: 1%
XRT: 56%
Postop XRT: 6%
median 60 median 69 PCM
3DCRT = 3-dimensional conformal radiotherapy; ADT = androgen deprivation therapy; brachy = brachytherapy; CaPSURE = Cancer of the Prostate Strategic Urologic Research Endeavor; CPDR = Center for Prostate Disease
Research; EBRT = external beam radiotherapy; IMRT = intensity modulated radiotherapy; NA = not applicable; NR = not reported; OM = overall mortality; PCOS = Prostate Cancer Outcomes Study; PCM = prostate cancer
mortality; RP = radical prostatectomy; SEER = Surveillance, Epidemiology and End Results; XRT = radiotherapy.
a Low risk prostate cancer = prostate speciﬁc antigen (PSA) < 10, Stage T1c–2a, Gleason score  6; intermediate risk prostate cancer = PSA 10–20, Stage T2b–c, Gleason score 7; high risk prostate cancer = PSA > 20, Stage >T3,
Gleason score  8.
b Total study size is 7538, 6209 patients treated with either surgery or radiotherapy were included.
c Total study size is 31 903, 19 258 patients treated with either surgery or radiotherapy were included.
d Total study size is 770, 446 patients treated with either surgery or radiotherapy were included.
e Total study size is 34 502, 32 846 patients with nonmetastatic prostate cancer treated with either surgery or radiotherapy were included.
f Total study size is 67 087, 49 145 patients treated with either surgery or radiotherapy were included.
g Total study size is 453, 256 patients treated with either surgery or radiotherapy were included.
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E U RO P E AN URO L OG Y 7 0 ( 2 0 1 6 ) 2 1 – 3 026the same clinical cohorts over the same time period. To
prevent the duplication of patients, a single study was
chosen to represent each cohort for each comparison as
outlined in the Supplementary data.
3.1. Study description
Three studies were from single centers, five were from
multiple institutions, and the remaining 11 were from
administrative databases (Table 1). The inclusion criteria
and length of follow-up varied significantly between
included studies (Table 1). Some studies imposedminimum
age requirements while others imposed maximum age
requirements which resulted in significant differences in
age distribution between studies. Patients treated with
radiotherapy were generally older in all of the included
studies.
Most studies assessed the efficacy of EBRT with some
including patients treated with brachytherapy. Two studies
provided data restricted to patients treated with IMRT. The
dosage of radiation was only available for eight of 19 (42%)Table 2 – Absolute mortality rates for included studies
Author
Inclusion criteria Ove
RP
Abdollah (2012) Clinically localized, age 65–79 NA
Albersten (2007) Clinically localized, age < 75 10 yr: 17%a
Arvold (2011) Low risk or intermediate risk NA
Boorjian (2011) High risk 10 yr: 23%
Cooperberg (2010) Clinically localized NA
DeGroot (2013) ‘‘Candidate for therapy’’:
low and intermediate risk
NA
Hoffman (2013) Clinically localized, age 55–74 15 yr: 35%a
Jeldres (2008) Age > 70 10 yr: 40.7%
15 yr: 72.7%
Kibel (2012) Clinically localized 10 yr: 11.1%
Ladjevardi (2010) T1–3, N0–X, M0–X,
PSA<20, age < 75
Relative survival i
given resulting in
survival estimates
100% and therefor
mortality < 0.
Lee (2014) Clinically localized high risk NA
Merglen (2007) Clinically localized NA
Merino (2013) Clinically localized 5 yr: 3.8%
7 yr: 6.3%
Rice (2013) Low risk, age > 70 10 yr: 18%a
Sooriakumaran (2014) All 10 yr low: 10%a
10 yr int: 15%a
10 yr high: 20%a
Sun (2013) Clinically localized, age 65–80 10 yr: 20%
Tewari (2007) Clinically localized,
high risk, age < 75
10 yr: 54%
Westover (2012) Clinically localized, Gleason
score 8–10, age < 75
NA
Zelefsky (2010) T1c–T3b NA
ADT = androgen deprivation therapy; brachy = brachytherapy; EBRT = external
PSA = prostate speciﬁc antigen; RP = radical prostatectomy; RT = radiotherapy; X
a Denotes that estimate is imputed from a graph or ﬁgure in the original manusstudies. Brachytherapy dosage was in keeping with
standard recommended doses, while only two studies
provided ‘‘dose-escalated’’ EBRT treatments to all patients
[7,15]. There was considerable variability in the use of
adjuvant or salvage therapies. In some studies, patients
receiving these treatments were excluded while in others
all patients received adjuvant therapies.
Study inclusion criteria, including patient age and
disease characteristics, significantly affectedmortality rates
for both all-cause and prostate cancer-specific mortality
(Table 2). Overall mortality rates significantly exceeded
prostate cancer-specific mortality, particular in patients
with low-risk disease. Covariates included in the adjusted
models varied significantly between studies though typi-
cally included age, clinical stage, Gleason score, and
Charlson comorbidity (Supplementary Table 1).
3.2. Risk of bias assessment
The majority of included studies were felt to have low to
moderate risk of bias (Table 3). Some studies usedrall mortality Prostate cancer mortality
XRT RP XRT
NA 10 yr low/int: 1.4%
10 yr high: 6.8%
10 yr low/int: 3.9%
10 yr high: 11.5%
10 yr: 22%a 10 yr low: 3%
10 yr int: 6%
10 yr high: 10%
10 yr low: 7%
10 yr int: 12%
10 yr high: 20%
NA 10 yr low: 0.4%a
10 yr int: 0%a
10 yr low: 0.8%a
10 yr int: 3.5%a
10 yr RT + ADT: 33%
10 yr RT: 48%
10 yr: 8% 10 yr RT + ADT: 8%
10 yr RT: 12%
NA 10 yr: 5%a 10 yr: 12%a
NA NA NA
15 yr: 58%a NA NA
10 yr: 69.7%
15 yr: 86.7%
NA NA
10 yr EBRT: 17.4%
10 yr brachy: 18.3%
10 yr: 1.8% 10 yr EBRT: 2.9%
10 yr brachy: 2.3%
s
>
e
NA 10 yr: 10%a 10y r: 20%a
NA 10 yr: 17% 10 yr: 25%
5 yr: 11.6%
7 yr: 16.9%
7 yr: 1.9% 7 yr: 7.9%
10 yr: 30%a
10 yr low: 16%a
10 yr int: 22%a
10 yr high: 30%a
10 yr low: 1%a
10 yr int: 3%a
10 yr high: 8%a
10 yr low: 1%a
10 yr int:8%a
10 yr high: 15%a
10 yr: 37% NA NA
10 yr: 75% 10 yr: 25% 10 yr: 43%
NA 5 yr: 0% 5 yr: 1.5%
NA 8 yr: 1.4% 8 yr: 4.7%
beam radiotherapy; NA = not applicable or assessed in the manuscript;
RT = radiotherapy.
cript.
Table 3 – Newcastle-Ottawa Scale for risk of bias assessment of studies included in the meta-analysis
Study Selection Comparability Outcome Overall
Representativeness
of exposed
cohort
Selection of
nonexposed
Ascertainment
of exposure
Outcome
not present
at start
Assessment
of outcome
Adequate
follow-up
length
Adequacy
of follow-up
Abdollah (2012) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 7
Albertsen[3_TD$DIFF] (2007) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 8
Arvold [3_TD$DIFF] (2011) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 5
Boorjian [3_TD$DIFF] (2011) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 7
Cooperberg [3_TD$DIFF] (2010) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 7
DeGroot [3_TD$DIFF] (2013) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 8
Hoffman[3_TD$DIFF] (2013) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 9
Jeldres [3_TD$DIFF] (2008) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 8
Kibel[3_TD$DIFF] (2012) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 8
Ladjevardi[3_TD$DIFF] (2010) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 8
Lee[3_TD$DIFF] (2014) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 8
Merglen [3_TD$DIFF] (2007) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 9
Merino [3_TD$DIFF] (2013) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 7
Rice [3_TD$DIFF] (2013) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 8
Sooriakumaran[3_TD$DIFF] (2014) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 9
Sun[3_TD$DIFF] (2013) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 7
Tewari[3_TD$DIFF] (2007) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 7
Westover[3_TD$DIFF] (2012) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 6
Zelefsky[3_TD$DIFF] (2010) [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] [TD$INLINE] 7
E U RO P E AN URO LOGY 7 0 ( 2 0 1 6 ) 2 1 – 3 0 27radiotherapy and surgery patients from different clinical
centers, thus introducing the risk of a selection bias. The
adequacy of follow-up was often not described in the
included studies which raise concern for attrition bias.
[(Fig._2)TD$FIG]
Fig. 2 – Forrest plot assessing the risk of (a) overall mortality and (b) prostate
prostate cancer.
CI = confidence interval; IV = inverse variance; SE = standard error.3.3. Overall mortality
Ten studies reporting on 95 791 patients were aggregated to
assess the effect of treatment modality on overall mortality.cancer-specific mortality following radiotherapy and surgery for
Table 4 – Subgroup analysis assessing risk of overall mortality and prostate cancer-specific mortality following treatment with surgery or
radiotherapy
Overall mortality Prostate cancer-speciﬁc mortality
Adjusted HR (95% CI, p value) I2 [3_TD$DIFF] Adjusted HR (95% CI, p value) I2
Risk category
Low risk 1.47 (1.19–1.83, p = 0.0004) 59% 1.70 (1.36–2.13, p < 0.00001) 0%
Intermediate risk 1.50 (1.24–1.82, p < 0.0001) NA 1.80 (1.45–2.25, p < 0.0001) 0%
High risk 1.88 (1.64–2.16, p < 0.00001) 0% 1.83 (1.51–2.22, p = 0.0001) 42%
Radiotherapy modality
EBRT (CRT and IMRT) 1.69 (1.55–1.85, p < 0.00001) 8% 2.26 (1.94–2.63, p < 0.00001) 0%
IMRT No studies available 2.26 (1.21–4.21, p = 0.01) 0%
Brachytherapy 1.70 (1.40–2.10, p < 0.001) NA 1.58 (1.01–2.49, p = 0.05) 0%
Duration of follow-up
<5 yr 1.54 (1.38–1.71, p < 0.00001) 0% 1.51 (0.25–9.19, p = 0.66) 89%
5–8 yr 1.73 (1.49–2.02, p < 0.00001) 18% 1.80 (1.57–2.05, p < 0.00001) 0%
>8 yr 1.74 (1.55–1.95, p < 0.00001) 0% 2.26 (1.60–3.20, p < 0.00001) 65%
Era of accrual
Early 1.75 (1.57–1.97, p < 0.00001) 5% 2.04 (1.54–2.72, p < 0.00001) 44%
Later 1.59 (1.48–1.70, p < 0.00001) 0% 2.12 (1.69–2.66, p < 0.00001) 58%
Geographic region
United States 1.63 (1.54–1.73, p < 0.00001) 0% 2.11 (1.65–2.69, p < 0.00001) 59%
Rest of the world 1.65 (1.55–1.76, p < 0.0001) 42% 1.85 (1.59–2.15, p < 0.00001) 0%
CI = conﬁdence interval; CRT = conformal radiation therapy; EBRT = external beam radiotherapy; HR = hazard ratio; IMRT = intensity modulated radiotherapy;
NA = not applicable.
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risk of overall mortality compared with those treated with
radical prostatectomy (aHR1.63, 95% confidence interval [CI]
1.54–1.73, p< 0.00001; I2 = 0%; Fig. 2a). Where authors
provided outcome data for patients treated with radiothera-
py alone and radiotherapy with androgen deprivation
therapy (ADT),weused the aggregate results for bothgroups.
We found a similar direction of effect whenwe examined
patients with low risk prostate cancer (aHR 1.47, 95% CI
1.19–1.83, p = 0.0004, I2 = 59%), intermediate risk prostate
cancer (aHR1.50, 95% CI 1.24–1.82, p < 0.0001; I2 = N/A), or
high risk prostate cancer (aHR 1.88, 95% CI 1.64–2.16,
p < 0.00001; I2 = 0%).
Further subgroup analyses did not differ in direction from
the primary results (Table 4). Patients treated with radio-
therapy who were treated in the earlier era (study accrual
periodprior to2005)had similaroutcomes to those treated in
the newer era (p = 0.14; Table 4). While assessing by
radiotherapy modality, we found a similar risk for patients
treated with EBRT (conformal radiation therapy [CRT] or
IMRT) and with brachytherapy (Table 4). No studies were
identified that reported on the risk of overall survival while
comparing IMRT to surgery. There were no ‘‘between group’’
differences observed with respect to duration of follow-up
(p = 0.24; I2 = 30%; Table 4). One study did not report follow-
upduration. Similarly, therewerenodifferencesbetween the
treatment eras (p = 0.14; I2 = 53%). Finally, there was no
difference observed whether the study cohort was from the
USA or the rest of the world (p = 0.52; I2 = 0%; Table 4).
3.4. Prostate cancer-specific mortality
Fifteen studies reporting on 118 830 patients were
aggregated to assess the effect of treatment modality on
prostate cancer specific mortality. Patients treated with
radiotherapy had an increased risk of prostate cancer-specific mortality (aHR 2.08, 95% CI 1.76–2.47, p < 0.00001;
I2 = 48%; Fig. 2b) compared with those treated with surgery.
We found similar results when we examined only
patients with low risk prostate cancer (aHR 1.70, 95% CI
1.36–2.13, p < 0.00001; I2 = 0%), intermediate risk prostate
cancer (aHR1.80, 95% CI 1.45–2.25, p < 0.0001; I2 = 0%), or
high risk prostate cancer (aHR 1.83, 95% CI 1.51–2.22,
p = 0.0001; I2 = 42%).
Subanalyses for this endpoint also had similar direction
of results to the primary analysis. We observed no between-
subgroup differences when examining the effect of study
era (p = 0.85; I2 = 0%; Table 4). Assessing the effect of
specific radiotherapymodalities, we found an increased risk
for those treated with EBRT (CRT or IMRT), IMRT alone, and
brachytherapy alone (Table 4). There were no ‘‘between-
group’’ differences observed with respect to duration of
follow-up (p = 0.47; I2 = 0%), although the magnitude of
effect increased with increasing length of follow-up
(Table 4). Two studies did not report follow-up duration.
Similarly, results were consistent regardless of geographic
location of publication (p = 0.26; I2 = 22%; Table 4).
3.5. Publication bias
We assessed publication bias using funnel plots comparing
effect size and measure of precision of the effect size for the
main analysis of our primary and secondary analyses
(Supplementary Fig. 1). We did not identify any evidence of
publication bias.
4. Discussion
In this review and meta-analysis of 19 studies with low to
moderate risk of bias, we identified an increased overall and
prostate cancer-specific mortality for patients treated with
radiotherapy compared with those treated with surgery for
E U RO P E AN URO LOGY 7 0 ( 2 0 1 6 ) 2 1 – 3 0 29clinically localized prostate cancer. These findings were
supported with subgroup analyses which assessed the
impact of prostate cancer risk category, radiotherapy
modality, duration of follow-up, era of study accrual, and
geographic region.
To our knowledge, this represents the most comprehen-
sive and up-to-date review on this topic. Petrelli et al [5]
conducted a meta-analysis examining the survival out-
comes among patients with only high risk prostate cancer
treated with surgery or radiotherapy [5]. They found better
overall and prostate cancer-specific survival for patients
treated with surgery compared with radiotherapy. A key
limitation of this study was that they used adjusted and
unadjusted odds ratios which do not take into account the
time-to-event outcome measures as our study has done
[16]. Other recent reviews have been restricted to
randomized controlled trials [17], to high-risk patients
[4], or did not provide aggregate risk estimates [18].
Two small randomized controlled trials have compared
survival outcomes for patients treated with surgery or
radiotherapy for prostate cancer [19,20]. These were largely
underpowered and have not been used to guide treatment
decision making. Other trials have closed prematurely due
to poor accrual [21] because of patients’ unwillingness to
leave their treatment to chance [22].
We performed a number of prespecified subgroup
analyses to explore potential areas of bias, but analyses
stratified by prostate cancer risk category, radiotherapy
modality, duration of follow-up, era of study accrual, and
geographic region did not differ from the overall analysis.
Recently, radiation dose escalation was associated with
improved overall survival in patients with intermediate-
and high-risk prostate cancer compared with standard
dosing [23]. While we were not able to ascertain specific
radiation doses frommany studies, themajority of included
patients were treated with standard-dose regimens.
Zelefsky et al [15] used dose-escalated IMRT (>81 Gy)
and found results similar to the other included studies.
We found statistically significant between-study het-
erogeneity for our pooled analysis of prostate cancer-
specific mortality, but not overall mortality. This is likely
due to increased uncertainty and methodologic differences
in assigning cause of death. Some studies used administra-
tive death records. Other studies used outcome determina-
tion at the discretion of the treating physician [15,24], and
yet others used a combination of death certificates and
physician correspondence [25,9].
Major strengths of this review include a comprehensive
search strategy, careful selection of studies, critical and
thorough quality appraisal of included studies, a priori
subgroup analyses, and the use an outcome measure which
incorporates the time-to-event nature of the data and
adjusts for known confounders. Ameta-analysis depends on
the validity of the included studies to draw accurate
conclusions. Therefore, a key limitation of our study is the
effect of residual confounding as this analysis is based on
observational data. It is well established that patients
treatedwith radiotherapy tend to be older and have a higher
level of comorbidity. As the vast majority of the includedstudies measured comorbidity using the Charlson comor-
bidity index, there remains the potential for heterogeneity
within the categories resulting in residual confounding.
Giordano et al [26] postulate that this may be driven by
unmeasured differences in functional status and self-
reported health. While current statistical methodologies
such as regression andmatching are unable to fully adjust for
selection bias and unmeasured confounders [26], we only
usedmultivariable aHRs inour study inanattempt toprovide
more accurate risk estimates. Also, the use of salvage
therapies may explain some of the survival differences
between the groups. Patients initially treated with surgery
may undergo salvage radiotherapy while patients who fail
after radiotherapy are less often offered salvage surgery. In
contrast, patientswith recurrence followingradiotherapyare
typically managedwith ADT. In the included studies, the use
of adjuvant or salvage radiotherapy varied—many did not
specify the use of this therapy, some excluded these patients,
and usage ranged from3–10% in the remainder. Additionally,
the use of ADT, either as adjuvant or salvage therapy, varied
widely as expected given the heterogeneity of prostate
cancer disease characteristics included. ADT usage was
higher in patients treated with radiotherapy in the vast
majority of studies. This is in keeping with expectations as
the use of neoadjuvant, concurrent, or adjuvant ADT is often
part of standard care in the radiotherapy setting, as its benefit
has been shown in several large randomized radiotherapy
studies. Also, for overall survival, therewere insufficient data
to assess the efficacy of IMRT, which has largely supplanted
three-dimensional CRT in many jurisdictions [27]. Finally, a
pathological review is rarely undertaken in large databases.
As a result, heterogeneity may exist within pathological
grading in these data sourcesdue to interobserver variability.
Implications for future research assessing the compara-
tive efficacy of surgery and radiotherapy in prostate cancer
will largely depend on the results of the upcoming
randomized ProtecT trial [28]. Clinical implications will
likely depend on the congruence of the observational and
randomized data. Prospective data derived from random-
ized controlled trials will allow for better management of
confounding in addition to allowing for longitudinal
quality-of-life assessment which is unavailable from large
administrative datasets. As is emphasized in current clinical
guidelines, both treatment modalities should be discussed
with eligible patients prior to initiation of either therapy
[1]. Given that current clinical guidelines do not discrimi-
nate patients by age and comorbidity level, the results of
this study would be an important consideration for patients
and physicians.5. Conclusions
We identified an increased risk of overall and prostate
cancer-specific mortality for patients treated with radio-
therapy compared with surgery after adjustment for
common patient and tumor prognostic factors. Methodo-
logic limitations of the observational studies included
should be considered while interpreting these results.
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